Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL29273171 | 0.89 | CA1 (0.43) | CA4FAHD1CA1CA2MEN1 | |
| Bicarbonate SCHEMBL3824855 | 0.88 | CA4 (0.43) | CA4FAHD1CA1CA2MEN1 | |
| Bicarbonate SCHEMBL10755209 | 0.88 | — | — | |
| Bicarbonate SCHEMBL1430835 | 0.88 | — | — | |
| Sulfurous Acid SCHEMBL9928922 | 0.88 | — | — | |
| Bicarbonate SCHEMBL6566883 | 0.86 | CA4 (0.35) | CA4FAHD1CA1CA2MEN1 | |
| Bicarbonate SCHEMBL10774604 | 0.85 | CA4 (0.50) | CA4FAHD1CA1CA2MEN1 | |
| Sulfurous Acid SCHEMBL28661780 | 0.84 | — | — | |
| Sulfurous Acid SCHEMBL889 | 0.83 | — | — | |
| Sulfurous Acid SCHEMBL29410199 | 0.83 | CA1 (0.50) | CA4FAHD1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113598209-A | Method for reducing acrylamide content in baked food and food additive composition used in method | 浙江省农业科学院 | 2021-11-05 | — | — | CN | disclosed |
| US-20120004391-A2 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Cyanine Technologies S.p.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-20110118438-A1 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Cyanine Technologies S.p.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-7892297-B2 | Cyanin-type compounds having an alkynyl linker arm | Cyanine Technologies S.p.A. (IT) | 2011-02-22 | — | — | US | disclosed |
| CN-101239953-A | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-100340562-C | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2007-10-03 | — | — | CN | disclosed |
| CN-1938323-A | Silinane compounds as cysteine protease inhibitors | SCHERING AG (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-20060230554-A1 | Cyanin-type compounds having an alkynyl linker arm | CYANINE TECHNOLOGIES S. P. A. (IT) | 2006-10-19 | — | — | US | disclosed |
| EP-1654327-A1 | CYANIN-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Caputo, Giuseppe (IT) | 2006-05-10 | — | — | EP | disclosed |
| CN-1681822-A | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005014723-A1 | CYANIN-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | CAPUTO GIUSEPPE (IT) | 2005-02-17 | — | — | WO | disclosed |
| CN-1156476-C | 1-cycloalkyl-1, 8-naphthyridin-4-one derivatives as phosphodiesterase type IV inhibitors | ��һ��������ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20030138468-A1 | Topical compositions that can prevent the contact and access of toxic chemicals and irritants to the skin for extended periods of time; can be added to conditioners, cleansing agents | LOPEZ ARMANDO R (US) | 2003-07-24 | — | — | US | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-6331548-B1 | PREVENTION OR TREATMENT OF CYTOKINE RELATED DISEASES | SUNTORY LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| CN-1256693-A | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase IV inhibitory activity | SUNTORY LTD (JP) | 2000-06-14 | — | — | CN | disclosed |
| EP-0978516-A1 | 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY | SUNTORY LIMITED (JP) | 2000-02-09 | — | — | EP | disclosed |
| US-5225422-A | Antiallergens, antiinflammatory agents | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0516069-A1 | Leukotriene B4 antagonist | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118438-A1 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | ACR, RNGTT, NCL | CA4 270/4885FAHD1 4292/4885CA1 2253/4885 |
| US-20120004391-A2 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | ACR, RNGTT, NCL | CA4 270/4885FAHD1 4292/4885CA1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.